报价延迟最少15分钟:2026/03/09 12:52 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
255.82 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
6.84/6.52
|
|
企业价值
7.42B
|
| 资产负债 |
|
每股账面净值
41.72
|
| 现金流量 |
|
现金流量率
0.03
|
| 损益表 |
|
收益
389.13M
|
|
每股收益
0.29
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company usesits patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates asone operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan. |
